An independent peptide reference — no sellers, every claim sourced

Orforglipron

Also known as Foundayo, LY3502970

Not a peptide: an oral small-molecule GLP-1 receptor agonist, approved for weight management.

clinically proven Metabolic & weight approved drug

At a glance

Category
Metabolic & weight
Status
approved drug
Route
oral, once daily, with or without food and without water restrictions
Half-life
roughly 25-70 hours across studies; approximately 29-49 hours in most reports, long enough for once-daily oral dosing
Onset
weight loss from the first weeks; weight was still declining at 72 weeks in the pivotal trial
Sequence
None — orforglipron is not a peptide. It is a synthetic non-peptide small molecule (CAS 2212020-52-3).

Approved by the FDA on 1 April 2026 as Foundayo, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight and at least one weight-related comorbid condition 6. It was the first new molecular entity approved under the FDA's Commissioner's National Priority Voucher pilot programme, issued 50 days after filing and 294 days before its PDUFA date of 20 January 2027, which is why review was unusually fast 6. Development in type 2 diabetes continues in the ACHIEVE programme. Developed by Eli Lilly. Prescription only.

Doping status: Not listed by WADA

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

Mechanism of action

Orforglipron is included in this reference because people searching for peptides encounter it constantly, but it is worth stating plainly: it is not a peptide. It is a conventional small organic molecule that binds an allosteric site on the GLP-1 receptor and activates it. Everything that follows from that activation is familiar, but the chemistry that gets it there is not.

The practical consequence of being a small molecule is oral bioavailability. Peptide GLP-1 agonists are digested in the gut; the only oral peptide product on the market, oral semaglutide, needs an absorption enhancer, must be taken fasting with a small sip of water, and requires waiting 30 minutes before eating or taking anything else. Orforglipron has no such restrictions — no food or water constraints, any time of day — because it is absorbed like an ordinary drug.

At the receptor, orforglipron produces the standard GLP-1 pharmacology: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and central appetite reduction. It is a partial agonist and is biased away from beta-arrestin recruitment, but as with other biased agonists in this space, the clinical relevance of that signalling profile has not been isolated in any trial.

One genuinely notable species difference: orforglipron is not pharmacologically active at the rodent GLP-1 receptor and did not produce thyroid C-cell tumours in rodent carcinogenicity studies. It nonetheless carries the class boxed warning, because it is active at the human receptor and the regulator was unwilling to assume the rodent finding is irrelevant when it could not be tested in the usual model.

What the research shows

Orforglipron has a completed, published phase 3 obesity trial with over a year of follow-up and a phase 3 diabetes programme, and is now an approved product. The evidence is solid for what it covers. The honest comparison point is that the weight effect — 11.2% at the top dose over 72 weeks, against 2.1% on placebo — is meaningfully smaller than injectable semaglutide 2.4 mg or tirzepatide. Its advantage is the route, not the effect size.

Research in humans

ATTAIN-1 (New England Journal of Medicine, 2025) randomised adults with obesity, or overweight with a weight-related condition and without diabetes, to three orforglipron doses or placebo for 72 weeks. Mean weight reductions were 7.5%, 8.4% and 11.2% at the low, medium and high doses versus 2.1% with placebo. Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol all improved significantly 1. Adverse events led to discontinuation in 5.3-10.3% of treated participants versus 2.7% on placebo 1. In type 2 diabetes, ACHIEVE-1 (New England Journal of Medicine, 2025) showed HbA1c reduction in early type 2 diabetes, and ACHIEVE-5 (JAMA, 2026) evaluated orforglipron added to titrated insulin glargine.

Animal and lab research

Orforglipron is not pharmacologically active at the rodent GLP-1 receptor, which means the standard rodent carcinogenicity model cannot answer the thyroid C-cell question for this compound. It did not produce tumours in rodents, but the label is explicit that this is uninformative rather than reassuring, and the boxed warning is retained on the basis of the class finding.

Caveats. The trials were funded and conducted by Eli Lilly. The weight effect is smaller than that of the injectable incretins, and there is as yet no published head-to-head trial against semaglutide or tirzepatide in obesity. Gastrointestinal discontinuation rates rise steeply with dose. There is no completed cardiovascular outcome trial. The approval came 294 days ahead of its PDUFA date under a priority voucher programme, so post-marketing surveillance is doing more of the safety work than usual. Long-term and rare adverse effects are not yet characterised.

What it is used for

  • Chronic weight management in adults with obesity, or overweight with at least one weight-related comorbid condition, alongside a reduced-calorie diet and increased physical activity (approved indication) 6
  • Type 2 diabetes mellitus — under investigation in the ACHIEVE phase 3 programme; not an approved indication at the time of writing
  • Of practical interest to people who will not or cannot inject, since it is the first oral small-molecule GLP-1 agonist approved for weight management

Dosing

Dose
0.8 mg to 17.2 mg once daily (approved tablet strengths: 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg)
Frequency
once daily, at any time of day, with or without food, with no water restriction
Route
Oral tablet
Duration
Chronic
  • Approved titration schedule: 0.8 mg once daily to start; after at least 30 days, increase to 2.5 mg once daily; after at least a further 30 days, increase to 5.5 mg once daily; thereafter escalate as needed and as tolerated to 9 mg, 14.5 mg or 17.2 mg once daily, allowing at least 30 days at each step 56. The label sets the steps in days, not in weeks.
  • The maximum recommended dose is 17.2 mg once daily 56.
  • The doses reported in the published trials (6 mg, 12 mg and 36 mg) were of an investigational formulation. The approved product uses different strengths, and the prescribing information presents trial data as equivalent Foundayo dosages — roughly 5.5 mg, 9 mg and 17.2 mg. Trial numbers and label numbers are therefore not directly interchangeable.
  • The graduated titration exists to limit gastrointestinal adverse events, which are dose-related.
  • This is the official approved schedule reproduced as reference information, not treatment advice.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Protocols

Foundayo oral titration (weight management)

approved product information

Source: US prescribing information for Foundayo (orforglipron), Eli Lilly

Days 1-30 (at least)0.8 mg orally once daily
After 30 days2.5 mg orally once daily
After a further 30 days5.5 mg orally once daily
After a further 30 days9 mg, 14.5 mg or 17.2 mg orally once daily, based on response and tolerability, with at least 30 days between increases
Ceiling17.2 mg once daily

Steps are 30 days rather than four weeks, and above 5.5 mg the label does not fix a single maintenance dose but leaves it to response and tolerability. Tablets are swallowed whole, with or without food, no more than one a day. Unlike oral semaglutide there is no empty-stomach or water-volume restriction.

Grey-market oral GLP-1 use (user-reported)

user protocol — not validated

Source: The pattern reported on GLP-1 and weight-loss forums together with research-chemical vendor labelling of 'orforglipron' powder

This is not a validated schedule. It is a pattern that circulates among users and sellers, reproduced because it is what people actually follow — not because it has been tested. No trial established these doses, this interval or this duration, and nobody is checking what is in the vial. Treat every number below as an assertion, not a finding.

Reported starting amounta low single-milligram amount once daily, estimated rather than measured, self-titrated upward
Reported escalationincreased faster than the label's 30-day steps, chasing appetite effect or weight loss

The label is a film-coated tablet in six precise strengths from 0.8 to 17.2 mg, escalated no faster than every 30 days to hold down dose-related gastrointestinal effects. What circulates is loose 'orforglipron' powder from the same vendors that sell grey-market semaglutide and tirzepatide, self-dosed by dissolving or suspending it and estimating an amount — and there the divergence is not mainly the schedule but the measurement: the label's doses are small milligram quantities delivered by a manufactured tablet, and weighing or diluting a powder to hit them accurately at home is unreliable. Users also self-titrate faster than the 30-day steps, which predictably worsens the nausea, vomiting and diarrhoea that are already the dose-limiting effects. This scene is thinner and newer than the injectable-peptide grey market, because orforglipron is a synthetic small molecule rather than a peptide: it cannot be identity-checked as easily, and nothing about a powder confirms it is actually the drug. No part of this has a published basis in people dosing this way.

Schedules are reproduced as their source states them. Units, IU and milligrams explains why the figures are not interchangeable between products.

Reconstitution

Storage
Store tablets as directed in the prescribing information, in the original container at room temperature.

Worked example

Not applicable. Orforglipron is a film-coated oral tablet. There is nothing to reconstitute, dissolve or inject.

Because orforglipron is a small molecule rather than a peptide, none of the handling considerations that apply to injectable peptides — bacteriostatic water, cold chain, reconstitution stability — are relevant here.

Safety

Side effects

  • Nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain — the most common adverse events, mostly mild to moderate, dose-related and concentrated during titration 6
  • Decreased appetite and abdominal pain
  • Discontinuation for adverse events in roughly 5-10% of treated participants in the pivotal trial, rising with dose
  • Eructation, flatulence, abdominal distension, gastro-oesophageal reflux disease and hair loss 6
  • Fatigue and headache
  • Modest increase in heart rate, a class effect
  • Acute pancreatitis — a labelled warning 6
  • Acute gallbladder disease — a labelled warning; gallstones and cholecystitis are most likely with rapid weight loss 6
  • Acute kidney injury due to volume depletion — a labelled warning 6
  • Hypoglycaemia — a labelled warning, and the risk rises when combined with insulin or a sulfonylurea 6
  • Pulmonary aspiration during general anaesthesia or deep sedation, from delayed gastric emptying and retained gastric contents — a labelled warning 6
  • Loss of fat-free mass alongside fat mass during weight reduction
  • Hypersensitivity reactions

Do not use if

  • Personal or family history of medullary thyroid carcinoma (MTC) 6
  • Multiple endocrine neoplasia syndrome type 2 (MEN 2) 6
  • Known serious hypersensitivity to orforglipron or any excipient
  • Boxed warning (FDA): the labelling for Foundayo includes a boxed warning for thyroid C-cell tumours 6. Pharmacologically active GLP-1 receptor agonists caused C-cell tumours in rodents; orforglipron itself is not active in rodents and produced no tumours, but the human relevance of the class finding has not been determined
  • History of pancreatitis — a relative contraindication; discontinue if pancreatitis is confirmed
  • Severe gastrointestinal disease including gastroparesis
  • Pregnancy and breastfeeding
  • Type 1 diabetes and diabetic ketoacidosis

Interactions

Delayed gastric emptying may alter the absorption of concomitantly administered oral medicines; caution is warranted with narrow-therapeutic-index drugs and with oral agents that depend on rapid onset. Combination with insulin or a sulfonylurea markedly increases hypoglycaemia risk and generally requires reducing the dose of those agents. The FDA states plainly that Foundayo should not be used in combination with another GLP-1 receptor agonist 6, and combination with a DPP-4 inhibitor is mechanistically redundant. As a small molecule it is subject to cytochrome P450-mediated drug interactions in a way that peptide GLP-1 agonists are not; consult the current prescribing information for the specific enzyme and transporter interactions. Anaesthesia guidance on modified preoperative fasting for GLP-1 receptor agonists applies.

Sources